Skip to main content

Table 3 Univariate analysis of factors regardingoverall survival (OS) and recurrence-free survival (RFS)

From: Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer

Variable

Categorisation

Tumour-related death (OS)

Tumour recurrence (RFS)

  

n

events

pc

n

events

pc

Clinicopathological data:

Tumour stagea

      
 

pT1

46

7

<0.0001

44

8

<0.0001

 

pT2

74

27

 

71

32

 
 

pT3

12

3

 

11

4

 
 

pT4

24

16

 

21

13

 

Lymph node statusa

      
 

pN0

68

9

<0.0001

66

13

<0.0001

 

pN1-3

83

40

 

79

42

 

Histological grade

      
 

G1

16

4

0.005

15

5

<0.0001

 

G2

67

16

 

62

15

 
 

G3

72

33

 

70

37

 

Multifocality

      
 

unifocal tumour

130

43

0.545

123

47

0.689

 

multifocal tumour

26

10

 

24

10

 

Histological type

      
 

ductal

130

44

0.787

126

52

0.432

 

lobular

11

5

 

9

2

 
 

other

13

4

 

11

3

 

Immunohistochemistry (IHC):

Oestrogen receptor status

      
 

negative (IRS 0–2)

41

17

0.094

41

21

0.034

 

positive (IRS 3–12)

89

26

 

84

26

 

Progesterone receptor status

      
 

negative (IRS 0–2)

95

43

<0.0001

88

43

0.001

 

positive (IRS 3–12)

41

5

 

41

6

 

HER2 IHC

      
 

weak (0–2+)

109

32

0.006

101

37

0.128

 

strong (3+)

25

14

 

25

12

 

RAI-3b

      
 

low (IRS 0–4)

78

25

0.816

76

29

0.897

 

abundant (IRS 5–12)

78

28

 

71

28

 
  1. aAccording to UICC: TNM Classification of Malignant Tumours. 6th edn (2002) Sobin LH, Wittekind CH (eds) Wiley: New York
  2. bRAI-3 immunoreactivity: low = IRS 0–4, abundant = IRS 5–12
  3. cLog-rank test (two-sided), bold face representing significant data (P < 0.05)